Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
November 02, 2022 16:01 ET
|
Rubius Therapeutics
Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius...
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
September 19, 2022 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red...
Rubius Therapeutics Announces Strategic Update
September 13, 2022 07:00 ET
|
Rubius Therapeutics
Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 ...
Rubius Therapeutics to Provide Strategic Update
September 12, 2022 16:30 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create...
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022 08:00 ET
|
Rubius Therapeutics
New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model Initial Clinical Results Expected in 2H’22 from Phase 1...
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
July 26, 2022 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
July 14, 2022 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
June 22, 2022 08:00 ET
|
Rubius Therapeutics
Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression Findings...
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
June 01, 2022 08:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
May 26, 2022 17:00 ET
|
Rubius Therapeutics
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...